These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27331244)

  • 1. Adoption of trastuzumab for breast cancer in four emerging countries in the use of health technology assessment: a case study.
    Martín-Ruiz E; Espín Balbino J; Lemgruber A; Caro-Martínez A; Lessa F; Olry-de-Labry-Lima A; Pérez-Velasco R; García-Mochón L
    J Comp Eff Res; 2016 Jul; 5(4):365-73. PubMed ID: 27331244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoption of the HPV vaccine: a case study of three emerging countries.
    Caro Martínez A; Espín Balbino J; Lemgruber A; Martín Ruiz E; Olry de Labry Lima A; García-Mochón L; Lessa F
    J Comp Eff Res; 2017 May; 6(3):195-204. PubMed ID: 28485691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?
    Garattini L; van de Vooren K; Curto A
    Health Policy; 2015 Feb; 119(2):212-6. PubMed ID: 25523144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment process of a cardiovascular medical device in four different settings.
    Olry de Labry Lima A; Espín Balbino J; Lemgruber A; Caro Martínez A; García-Mochón L; Martín Ruiz E; Lessa F
    J Comp Eff Res; 2017 Oct; 6(7):591-600. PubMed ID: 29039685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
    Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
    Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
    Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
    Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
    Pichon-Riviere A; Garay OU; Augustovski F; Vallejos C; Huayanay L; Bueno Mdel P; Rodriguez A; de Andrade CJ; Buendía JA; Drummond M
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):2-11. PubMed ID: 25989703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation.
    Carvalho VKDS; de Sousa MSA; Barreto JOM; da Silva EN
    BMC Health Serv Res; 2019 Oct; 19(1):762. PubMed ID: 31660957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 13. HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status.
    Rosselli D; Quirland-Lazo C; Csanádi M; Ruiz de Castilla EM; González NC; Valdés J; Abicalaffe C; Garzón W; Leon G; Kaló Z
    Value Health Reg Issues; 2017 Dec; 14():20-27. PubMed ID: 29254537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
    Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment in Poland and Scotland: comparison of process and decisions.
    Kolasa K; Wasiak R
    Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment for resource allocation decisions: are key principles relevant for Latin America?
    Pichon-Riviere A; Augustovski F; Rubinstein A; Martí SG; Sullivan SD; Drummond MF
    Int J Technol Assess Health Care; 2010 Oct; 26(4):421-7. PubMed ID: 20942985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
    Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
    Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMERGENCE OF "DRIVERS" FOR THE IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT.
    Castro Jaramillo HE; Moreno-Mattar O; Osorio-Cuevas D
    Int J Technol Assess Health Care; 2016 Jan; 32(4):300-306. PubMed ID: 27691993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.